Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof
AssigneeTaejoon Pharmaceutical Co., Ltd.
InventorsJoon Youb Lee, Youn Jae Shin, Hyun Won Seo, Dae Hun Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to a nanoemulsion ophthalmic composition and a preparation method thereof, wherein the nanoemulsion ophthalmic composition is obtained by mixing cyclosporine, castor oil, hydrophilic and hydrophobic emulsifiers, menthol, and an aqueous solvent, and thus exhibits excellent stability as well as ameliorating ocular irritation such as a feeling of grittiness, blurry vision, and the like.
Claims22
A stable nanoemulsion ophthalmic composition with low ocular irritation, comprising:
- cyclosporine in an amount of 0.07 w/v % to 0.2 w/v %;
- castor oil in an amount of 0.2 w/v % to less than five times the amount of cyclosporine;
- a hydrophilic emulsifier comprising polyoxyethylene castor oil in an amount of 1 w/v % to 5 w/v %;
- at least one hydrophobic emulsifier selected from the group consisting of polyethylene glycol and propylene glycol in an amount of 0.1 w/v % to 5 w/v %;
- menthol in an amount of 0.001 w/v % to less than 0.1 w/v %;
- and
- an aqueous solvent.
A method for preparing a stable nanoemulsion ophthalmic composition with low ocular irritation, the method comprising stirring and mixing:
- cyclosporine in an amount of 0.07 w/v % to 0.2 w/v %;
- castor oil in an amount of 0.2 w/v % to less than five times the amount of cyclosporine;
- a hydrophilic emulsifier comprising polyoxyethylene castor oil in an amount of 1 w/v % to 5 w/v %;
- at least one hydrophobic emulsifier selected from the group consisting of polyethylene glycol and propylene glycol in an amount of 0.1 w/v % to 5 w/v %;
- menthol in an amount of 0.001 w/v % to less than 0.1 w/v %;
- and
- an aqueous solvent,
- whereby a stable nanoemulsion ophthalmic composition with low ocular irritation is prepared.
A stable nanoemulsion ophthalmic composition with low ocular irritation, which is prepared by mixing:
- cyclosporine in an amount of 0.07 w/v % to 0.2 w/v %;
- castor oil in an amount of 0.2 w/v % to less than five times the amount of cyclosporine;
- a hydrophilic emulsifier comprising polyoxyethylene castor oil in an amount of 1 w/v % to 5 w/v %;
- at least one hydrophobic emulsifier selected from the group consisting of polyethylene glycol and propylene glycol in an amount of 0.1 w/v % to 5 w/v %;
- menthol in an amount of 0.001 w/v % to less than 0.1 w/v %;
- and
- an aqueous solvent.
A method for treating dry eye syndrome, the method comprising administering to a subject a stable nanoemulsion ophthalmic composition with low ocular irritation comprising:
- cyclosporine in an amount of 0.07 w/v % to 0.2 w/v %;
- castor oil in an amount of 0.2 w/v % to less than five times the amount of cyclosporine;
- a hydrophilic emulsifier comprising polyoxyethylene castor oil in an amount of 1 w/v % to 5 w/v %;
- at least one hydrophobic emulsifier selected from the group consisting of polyethylene glycol and propylene glycol in an amount of 0.1 w/v % to 5 w/v %;
- menthol in an amount of 0.001 w/v % to less than 0.1 w/v %;
- and
- an aqueous solvent.
Dependencies are inferred from the claim text.